|
1
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J ClinOncol. 27:6199–6206. 2009. View Article : Google Scholar
|
|
2
|
Nikolaou V and Stratigos AJ: Emerging
trends in the epidemiology of melanoma. Br J Dermatol. 170:11–19.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gandini S, Sera F, Cattaruzza MS, Pasquini
P, Picconi O, Boyle P and Melchi CF: Meta-analysis of risk factors
for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 41:45–60.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mihajlovic M, Vlajkovic S, Jovanovic P and
Stefanovic V: Primary mucosal melanomas: A comprehensive review.
Int J Clin Exp Pathol. 5:739–753. 2012.PubMed/NCBI
|
|
5
|
Soma PF, Pettinato A, Agnone AM, Donia C,
Improta G and Fraggetta F: Oral malignant melanoma: A report of two
cases with BRAF molecular analysis. Oncol Lett. 8:1283–1286. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buery RR, Siar CH, Katase N, Gunduz M,
Lefeuvre M, Fujii M, Inoue M, Setsu K and Nagatsuka H: NRAS and
BRAF mutation frequency in primary oral mucosal melanoma. Oncol
Rep. 26:783–787. 2011.PubMed/NCBI
|
|
7
|
Meleti M, Leemans CR, Mooi WJ, Vescovi P
and van der Waal I: Oral malignant melanoma: A review of the
literature. Oral Oncol. 43:116–121. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rapini RP, Golitz LE, Greer RO Jr,
Krekorian EA and Poulson T: Primary malignant melanoma of the oral
cavity. A review of 177 cases. Cancer. 55:1543–1551. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gu GM, Epstein JB and Morton TH Jr:
Intraoral melanoma: Long-term follow-up and implication for dental
clinicians. A case report and literature review. Oral Surg Oral Med
Oral Pathol Oral Radiol Endod. 96:404–413. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eggermont AM and Robert C: Melanoma: Smart
therapeutic strategies in immuno-oncology. Nat Rev Clin Oncol.
11:181–182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sabbatino F, Wang Y, Wang X, Ferrone S and
Ferrone CR: Emerging BRAF inhibitors for melanoma. Expert Opin
Emerg Drugs. 18:431–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Romano E, Schwartz GK, Chapman PB,
Wolchock JD and Carvajal RD: Treatment implications of the emerging
molecular classification system for melanoma. Lancet Oncol.
12:913–922. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Colombino M, Lissia A, Franco R, Botti G,
Ascierto PA, Manca A, Sini MC, Pisano M, Paliogiannis P, Tanda F,
et al: Unexpected distribution of cKIT and BRAF mutations among
southern italian patients with sinonasal melanoma. Dermatology.
226:279–284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong CW, Fan YS, Chan TL, Chan AS, Ho LC,
Ma TK, Yuen ST and Leung SY: Cancer Genome Project: BRAF and NRAS
mutations are uncommon in melanomas arising in diverse internal
organs. J Clin Pathol. 58:640–644. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cohen Y, Rosenbaum E, Begum S, Goldenberg
D, Esche C, Lavie O, Sidransky D and Westra WH: Exon 15 BRAF
mutations are uncommon in melanomas arising in nonsun-exposed
sites. Clin Cancer Res. 10:3444–3447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edwards RH, Ward MR, Wu H, Medina CA,
Brose MS, Volpe P, Nussen-Lee S, Haupt HM, Martin AM, Herlyn M, et
al: Absence of BRAF mutations in UV protected mucosal melanomas. J
Med Genet. 41:270–272. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Uhara H, Ashida A, Koga H, Ogawa E,
Uchiyama A, Uchiyama R, Hayashi K, Kiniwa Y and Okuyama R: NRAS
mutations in primary and metastatic melanomas of Japanese patients.
Int J Clin Oncol. 19:544–548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thompson L: World health organization
classification of tumours: Pathology and genetics of head and neck
tumours. Ear Nose Throat J. 85:742006.PubMed/NCBI
|
|
20
|
Curtin JA, Busam K, Pinkel D and Bastian
BC: Somatic activation of KIT in distinct subtypes of melanoma. J
Clin Oncol. 24:4340–4346. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ellerhorst JA, Greene VR, Ekmekcioglu S,
Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald
JE, Wei Q and Grimm EA: Clinical correlates of NRAS and BRAF
mutations in primary human melanoma. Clin Cancer Res. 17:229–235.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qu J, Yu F, Hong Y, Guo Y, Sun L, Li X,
Zhang J, Zhang H, Shi R, Chen F and Li T: Underestimated PTCH1
mutation rate in sporadic keratocysticodontogenic tumors. Oral
Oncol. 51:40–45. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Adzhubei I, Jordan DM and Sunyaev SR:
Predicting functional effect of human missense mutations using
polyphen-2. Curr Protoc Hum Genet: Chapter 7. Unit7.20. 2013.
|
|
24
|
Wang K, Li M and Hakonarson H: ANNOVAR:
Functional annotation of genetic variants from next-generation
sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Si L, Kong Y, Xu X, Flaherty KT, Sheng X,
Cui C, Chi Z, Li S, Mao L and Guo J: Prevalence of BRAF V600E
mutation in Chinese melanoma patients: Large scale analysis of BRAF
and NRAS mutations in a 432-case cohort. Eur J Cancer. 48:94–100.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: PRISMA Group: Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. PLoS Med. 6:e10000972009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cohen Y, Goldenberg-Cohen N, Akrish S,
Shani T, Amariglio N, Dratviman-Storobinsky O, Kaplan I, Barshack I
and Hirshberg A: BRAF and GNAQ mutations in melanocytic tumors of
the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol.
114:778–784. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rivera RS, Nagatsuka H, Gunduz M, Cengiz
B, Gunduz E, Siar CH, Tsujigiwa H, Tamamura R, Han KN and Nagai N:
C-kit protein expression correlated with activating mutations in
KIT gene in oral mucosal melanoma. Virchows Arch. 452:27–32. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Antonescu CR, Viale A, Sarran L,
Tschernyavsky SJ, Gonen M, Segal NH, Maki RG, Socci ND, DeMatteo RP
and Besmer P: Gene expression in gastrointestinal stromal tumors is
distinguished by KIT genotype and anatomic site. Clin Cancer Res.
10:3282–3290. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peyssonnaux C and Eychène A: The
Raf/MEK/ERK pathway: New concepts of activation. Biol Cell.
93:53–62. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Platz A, Egyhazi S, Ringborg U and Hansson
J: Human cutaneous melanoma; a review of NRAS and BRAF mutation
frequencies in relation to histogenetic subclass and body site. Mol
Oncol. 1:395–405. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Malumbres M and Barbacid M: RAS oncogenes:
The first 30 years. Nat Rev Cancer. 3:459–465. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alexeev V and Yoon K: Distinctive role of
the cKit receptor tyrosine kinase signaling in mammalian
melanocytes. J Invest Dermatol. 126:1102–1110. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lennartsson J, Jelacic T, Linnekin D and
Shivakrupa R: Normal and oncogenic forms of the receptor tyrosine
kinase kit. Stem Cells. 23:16–43. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Omholt K, Grafström E, Kanter-Lewensohn L,
Hansson J and Ragnarsson-Olding BK: KIT pathway alterations in
mucosal melanomas of the vulva and other sites. Clin Cancer Res.
17:3933–3942. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Beadling C, Jacobson-Dunlop E, Hodi FS, Le
C, Warrick A, Patterson J, Town A, Harlow A, Cruz F III, Azar S, et
al: KIT gene mutations and copy number in melanoma subtypes. Clin
Cancer Res. 14:6821–6828. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schoenewolf NL, Bull C, Belloni B,
Holzmann D, Tonolla S, Lang R, Mihic-Probst D, Andres C and Dummer
R: Sinonasal, genital and acrolentiginous melanomas show distinct
characteristics of KIT expression and mutations. Eur J Cancer.
48:1842–1852. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gardberg M, Talvinen K, Kaipio K, Iljin K,
Kampf C, Uhlen M and Carpén O: Characterization of
diaphanous-related formin FMNL2 in human tissues. BMC Cell Biol.
11:552010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu XL, Zeng YF, Guan J, Li YF, Deng YJ,
Bian XW, Ding YQ and Liang L: FMNL2 is a positive regulator of cell
motility and metastasis in colorectal carcinoma. J Pathol.
224:377–388. 2011. View Article : Google Scholar : PubMed/NCBI
|
